Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Read More: Jim Cramer Says He Can't Recommend This Major Automaker, Ceva Is 'Way Too High'During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
在市场动荡和不确定的时期，许多投资者会转向股息收益股，这些通常是具有较高的自由现金流并以高红利派息奖励股东的公司。
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.
Benzinga的读者可以通过访问分析师股票评级页面，查看他们最喜欢的股票的最新分析师观点。交易员可以浏览Benzinga庞大的分析师评级数据库，包括按照分析师准确度排序。
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
以下是医疗保健板块三只高收益股票最准确的分析师评级。
Royalty Pharma plc (NASDAQ:RPRX)
罗伊尔蒂制药股份有限公司（NASDAQ：RPRX）
- Dividend Yield: 3.05%
- Citigroup analyst Andrew Baum maintained a Buy rating and cut the price target from $60 to $40 on Oct. 25. This analyst has an accuracy rate of 72%.
- Morgan Stanley analyst Terence Flynn maintained an Overweight rating and raised the price target from $48 to $51 on July 11. This analyst has an accuracy rate of 69%.
- Recent News: On Nov. 4, Royalty Pharma and Syndax Pharmaceuticals entered into $350 million royalty funding agreement for Niktimvo.
- Benzinga Pro's real-time newsfeed alerted to latest RPRX news.
- 股息率：3.05%
- 花旗集团分析师Andrew Baum维持买入评级，并将价格目标从60万亿美元降至40美元。这位分析师的准确率为72%。
- 摩根士丹利分析师Terence Flynn维持增持评级，并将价格目标从48美元上调至51美元，日期为7月11日。这位分析师的准确率为69%。
- 近期资讯：11月4日，Royalty Pharma和syndax pharmaceuticals达成了一项值35000万美元的版税资金协议，用于Niktimvo。
- Benzinga Pro的实时新闻提醒了最新的RPRX资讯。
Johnson & Johnson (NYSE:JNJ)
强生公司（纽交所股票代码：JNJ）
- Dividend Yield: 3.13%
- Citigroup analyst Joanne Wuensch maintained a Buy rating and raised the price target from $180 to $185 on Oct. 16. This analyst has an accuracy rate of 77%.
- Wells Fargo analyst Larry Biegelsen maintained an Equal-Weight rating and increased the price target from $163 to $166 on Oct. 16. This analyst has an accuracy rate of 72%.
- Recent News: On Oct. 28, Johnson & Johnson announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn's disease.
- Benzinga Pro's real-time newsfeed alerted to latest JNJ news.
- 股息收益率：3.13％
- 花旗集团分析师Joanne Wuensch维持买入评级，并将价格目标从180万亿美元提高至185美元于10月16日。该分析师的准确率为77%。
- 韦尔斯·法戈分析师Larry Biegelsen维持持平评级，并将价格目标从163万亿美元提高至166美元于10月16日。该分析师的准确率为72%。
- 近期资讯：约翰逊&约翰逊于10月28日宣布了Tremfya（guselkumab）用于克罗恩病的3期GRAVITI研究结果。
- Benzinga Pro的实时新闻提醒了最新的JNJ资讯。
Medtronic plc (NYSE:MDT)
美敦力（MDT）公司（纽交所MDT）
- Dividend Yield: 3.12%
- Truist Securities analyst Richard Newitter maintained a Hold rating and raised the price target from $90 to $93 on Oct. 14. This analyst has an accuracy rate of 74%.
- Citigroup analyst Joanne Wuensch maintained a Neutral rating and increased the price target from $85 to $92 on Oct. 1. This analyst has an accuracy rate of 77%.
- Recent News: Medtronic will report financial results for its second quarter of fiscal year 2025 on Tuesday, Nov. 19.
- Benzinga Pro's charting tool helped identify the trend in MDT stock.
- 股息收益率：3.12%
- Truist Securities 分析师 Richard Newitter 持有评级，于10月14日将价格目标从90万亿美元提高至93美元。该分析师的准确率为74%。
- 花旗集团分析师Joanne Wuensch维持中立评级，在10月1日将价格目标从85万亿美元提高至92美元。该分析师的准确率为77%。
- 近期资讯：美敦力将于2025财年第二季度的11月19日星期二发布财务业绩。
- Benzinga Pro的图表工具帮助识别了MDt股票的趋势。
Read More: Jim Cramer Says He Can't Recommend This Major Automaker, Ceva Is 'Way Too High'
阅读更多：吉姆·克雷默表示他无法推荐这家主要汽车制造商，Ceva的股价“太高了”。
